|
1
|
Niklinski J, Niklinska W, Chyczewski L,
Becker HD and Pluygers E: Molecular genetic abnormalities in
premalignant lung lesions: Biological and clinical implications.
Eur J Cancer Prev. 10:213–226. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Imai S, Armstrong CM, Kaeberlein M and
Guarente L: Transcriptional silencing and longevity protein
Sir2 is an NAD-dependent histone deacetylase. Nature.
403:795–800. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Blander G and Guarente L: The Sir2 family
of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee H, Kim KR, Noh SJ, Park HS, Kwon KS,
Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, et al: Expression of
DBC1 and SIRT1 is associated with poor prognosis for breast
carcinoma. Hum Pathol. 42:204–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bae HJ, Chang YG, Noh JH, Kim JK, Eun JW,
Jung KH, Kim MG, Shen Q, Ahn YM, Kwon SH, et al: DBC1 does not
function as a negative regulator of SIRT1 in liver cancer. Oncol
Lett. 4:873–877. 2012.PubMed/NCBI
|
|
6
|
Kuzmichev A, Margueron R, Vaquero A,
Preissner TS, Scher M, Kirmizis A, Ouyang X, Brockdorff N,
Abate-Shen C, Farnham P and Reinberg D: Composition and histone
substrates of polycomb repressive group complexes change during
cellular differentiation. Proc Natl Acad Sci USA. 102:1859–1864.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Solomon JM, Pasupuleti R, Xu L, McDonagh
T, Curtis R, DiStefano PS and Huber LJ: Inhibition of SIRT1
catalytic activity increases p53 acetylation but does not alter
cell survival following DNA damage. Mol Cell Biol. 26:28–38. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yeung F, Hoberg JE, Ramsey CS, Keller MD,
Jones DR, Frye RA and Mayo MW: Modulation of NF-kappaB-dependent
transcription and cell survival by the SIRT1 deacetylase. EMBO J.
23:2369–2380. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng HL, Mostoslavsky R, Saito S, Manis
JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW and Chua KF:
Developmental defects and p53 hyperacetylation in Sir2 homolog
(SIRT1)-deficient mice. Proc Natl Acad Sci USA. 100:10794–10799.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cohen HY, Miller C, Bitterman KJ, Wall NR,
Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R and Sinclair
DA: Calorie restriction promotes mammalian cell survival by
inducing the SIRT1 deacetylase. Science. 305:390–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brunet A, Sweeney LB, Sturgill JF, Chua
KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, et
al: Stress-dependent regulation of FOXO transcription factors by
the SIRT1 deacetylase. Science. 303:2011–2015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Naqvi A, Hoffman TA, DeRicco J, Kumar A,
Kim CS, Jung SB, Yamamori T, Kim YR, Mehdi F, Kumar S, et al: A
single-nucleotide variation in a p53-binding site affects
nutrient-sensitive human SIRT1 expression. Hum Mol Genet.
19:4123–4133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tseng RC, Lee CC, Hsu HS, Tzao C and Wang
YC: Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous
carcinoma and adenocarcinoma patients. Neoplasia. 11:763–770. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Johnson KR, Lehn DA and Reeves R:
Alternative processing of mRNAs encoding mammalian chromosomal
high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol.
9:2114–2123. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou X, Benson KF, Ashar HR and Chada K:
Mutation responsible for the mouse pygmy phenotype in the
developmentally regulated factor HMGI-C. Nature. 376:771–774. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chiappetta G, Avantaggiato V, Visconti R,
Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti
V, Santoro M, et al: High level expression of the HMGI (Y) gene
during embryonic development. Oncogene. 13:2439–2446.
1996.PubMed/NCBI
|
|
17
|
Chiappetta G, Tallini G, De Biasio MC,
Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro
A, Botti G, Fedele M, et al: Detection of high mobility group I
HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y)
expression represents a potential diagnostic indicator of
carcinoma. Cancer Res. 58:4193–4198. 1998.PubMed/NCBI
|
|
18
|
Fedele M, Bandiera A, Chiappetta G,
Battista S, Viglietto G, Manfioletti G, Casamassimi A, Santoro M,
Giancotti V and Fusco A: Human colorectal carcinomas express high
levels of high mobility group HMGI(Y) proteins. Cancer Res.
56:1896–1901. 1996.PubMed/NCBI
|
|
19
|
Tamimi Y, van der Poel HG, Denyn MM, Umbas
R, Karthaus HF, Debruyne FM and Schalken JA: Increased expression
of high mobility group protein I(Y) in high grade prostatic cancer
determined by in situ hybridization. Cancer Res. 53:5512–5516.
1993.PubMed/NCBI
|
|
20
|
Abe N, Watanabe T, Izumisato Y, Masaki T,
Mori T, Sugiyama M, Chiappetta G, Fusco A, Fujioka Y and Atomi Y:
Diagnostic significance of high mobility group I(Y) protein
expression in intraductal papillary mucinous tumors of the
pancreas. Pancreas. 25:198–204. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bandiera A, Bonifacio D, Manfioletti G,
Mantovani F, Rustighi A, Zanconati F, Fusco A, Di Bonito L and
Giancotti V: Expression of HMGI(Y) proteins in squamous
intraepithelial and invasive lesions of the uterine cervix. Cancer
Res. 58:426–431. 1998.PubMed/NCBI
|
|
22
|
Masciullo V, Baldassarre G, Pentimalli F,
Berlingieri MT, Boccia A, Chiappetta G, Palazzo J, Manfioletti G,
Giancotti V, Viglietto G, et al: HMGA1 protein over-expression is a
frequent feature of epithelial ovarian carcinomas. Carcinogenesis.
24:1191–1198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiappetta G, Botti G, Monaco M,
Pasquinelli R, Pentimalli F, Di Bonito M, D'Aiuto G, Fedele M,
Iuliano R, Palmieri EA, et al: HMGA1 protein overexpression in
human breast carcinomas: Correlation with ErbB2 expression. Clin
Cancer Res. 10:7637–7644. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grosschedl R, Giese K and Pagel J: HMG
domain proteins: Architectural elements in the assembly of
nucleoprotein structures. Trends Genet. 10:94–100. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thanos D and Maniatis T: The high mobility
group protein HMG I(Y) is required for NF-kappa B-dependent virus
induction of the human IFN-beta gene. Cell. 71:777–789. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fusco A and Fedele M: Roles of HMGA
proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sionov RV and Haupt Y: The cellular
response to p53: The decision between life and death. Oncogene.
18:6145–6157. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kruse JP and Gu W: Modes of p53
regulation. Cell. 137:609–622. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Esposito F, Tornincasa M, Federico A,
Chiappetta G, Pierantoni GM and Fusco A: High-mobility group A1
protein inhibits p53-mediated intrinsic apoptosis by interacting
with Bcl-2 at mitochondria. Cell Death Dis. 3:e3832012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pierantoni GM, Rinaldo C, Esposito F,
Mottolese M, Soddu S and Fusco A: High Mobility Group A1 (HMGA1)
proteins interact with p53 and inhibit its apoptotic activity. Cell
Death Differ. 13:1554–1563. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Esposito F, Tornincasa M, Chieffi P, De
Martino I, Pierantoni GM and Fusco A: High-mobility group A1
proteins regulate p53-mediated transcription of Bcl-2 gene. Cancer
Res. 70:5379–5388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pierantoni GM, Rinaldo C, Mottolese M, Di
Benedetto A, Esposito F, Soddu S and Fusco A: High-mobility group
A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic
activator HIPK2. J Clin Invest. 117:693–702. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sobin LH: The World Health Organization's
Histological Classification of Lung Tumors: A comparison of the
first and second editions. Cancer Detect Prev. 5:391–406.
1982.PubMed/NCBI
|
|
34
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Grbesa I, Pajares MJ, Martínez-Terroba E,
Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio
R and Montuenga LM: Expression of sirtuin 1 and 2 is associated
with poor prognosis in non-small cell lung cancer patients. PLoS
One. 10:e01246702015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH,
Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, et al: Expression of
DBC1 and SIRT1 is associated with poor prognosis of gastric
carcinoma. Clin Cancer Res. 15:4453–4459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
You TK, Kim KM, Noh SJ, Bae JS, Jang KY,
Chung MJ, Moon WS, Kang MJ, Lee DG and Park HS: Expressions of
E-cadherin, Cortactin and MMP-9 in pseudoepitheliomatous
hyperplasia and squamous cell carcinoma of the head and neck: Their
relationships with clinicopathologic factors and prognostic
implication. Korean J Pathol. 46:331–340. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Noh SJ, Baek HA, Park HS, Jang KY, Moon
WS, Kang MJ, Lee DG, Kim MH, Lee JH and Chung MJ: Expression of
SIRT1 and cortactin is associated with progression of non-small
cell lung cancer. Pathol Res Pract. 209:365–370. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luo J, Nikolaev AY, Imai S, Chen D, Su F,
Shiloh A, Guarente L and Gu W: Negative control of p53 by Sir2alpha
promotes cell survival under stress. Cell. 107:137–148. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Firestein R, Blander G, Michan S,
Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S,
de Cabo R, Fuchs C, et al: The SIRT1 deacetylase suppresses
intestinal tumorigenesis and colon cancer growth. PLoS One.
3:e20202008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang RH, Zheng Y, Kim HS, Xu X, Cao L,
Luhasen T, Lee MH, Xiao C, Vassilopoulos A, Chen W, et al:
Interplay among BRCA1, SIRT1 and Survivin during BRCA1-associated
tumorigenesis. Mol Cell. 32:11–20. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stunkel W, Peh BK, Tan YC, Nayagam VM,
Wang X, Salto-Tellez M, Ni B, Entzeroth M and Wood J: Function of
the SIRT1 protein deacetylase in cancer. Biotechnol J. 2:1360–1368.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen WY, Wang DH, Yen RC, Luo J, Gu W and
Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to
modulate p53-dependent DNA-damage responses. Cell. 123:437–448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jang KY, Noh SJ, Lehwald N, Tao GZ,
Bellovin DI, Park HS, Moon WS, Felsher DW and Sylvester KG: SIRT1
and c-Myc promote liver tumor cell survival and predict poor
survival of human hepatocellular carcinomas. PLoS One.
7:e451192012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang T, Rong N, Chen J, Zou C, Jing H,
Zhu X and Zhang W: SIRT1 expression is associated with the
chemotherapy response and prognosis of patients with advanced
NSCLC. PLoS One. 8:e791622013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jang KY, Kim KS, Hwang SH, Kwon KS, Kim
KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG and Moon WS:
Expression and prognostic significance of SIRT1 in ovarian
epithelial tumours. Pathology. 41:366–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jang SH, Min KW, Paik SS and Jang KS: Loss
of SIRT1 histone deacetylase expression associates with tumour
progression in colorectal adenocarcinoma. J Clin Pathol.
65:735–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jung W, Hong KD, Jung WY, Lee E, Shin BK,
Kim HK, Kim A and Kim BH: SIRT1 Expression is associated with good
prognosis in colorectal cancer. Korean J Pathol. 47:332–339. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sarhadi VK, Wikman H, Salmenkivi K, Kuosma
E, Sioris T, Salo J, Karjalainen A, Knuutila S and Anttila S:
Increased expression of high mobility group A proteins in lung
cancer. J Pathol. 209:206–212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dixit D, Sharma V, Ghosh S, Mehta VS and
Sen E: Inhibition of Casein kinase-2 induces p53-dependent cell
cycle arrest and sensitizes glioblastoma cells to tumor necrosis
factor (TNFα)-induced apoptosis through SIRT1 inhibition. Cell
Death Dis. 3:e2712012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Peck B, Chen CY, Ho KK, Di Fruscia P,
Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD and Lam EW: SIRT
inhibitors induce cell death and p53 acetylation through targeting
both SIRT1 and SIRT2. Mol Cancer Ther. 9:844–855. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kracikova M, Akiri G, George A,
Sachidanandam R and Aaronson SA: A threshold mechanism mediates p53
cell fate decision between growth arrest and apoptosis. Cell Death
Differ. 20:576–588. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zou T, Yang Y, Xia F, Huang A, Gao X, Fang
D, Xiong S and Zhang J: Resveratrol Inhibits CD4(+) T Cell
Activation by Enhancing the Expression and Activity of Sirt1. PLoS
One. 8:e751392013. View Article : Google Scholar : PubMed/NCBI
|
